CN118984835A - c-Jun拮抗剂肽 - Google Patents

c-Jun拮抗剂肽 Download PDF

Info

Publication number
CN118984835A
CN118984835A CN202380033105.4A CN202380033105A CN118984835A CN 118984835 A CN118984835 A CN 118984835A CN 202380033105 A CN202380033105 A CN 202380033105A CN 118984835 A CN118984835 A CN 118984835A
Authority
CN
China
Prior art keywords
amino acid
jun
seq
peptide
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380033105.4A
Other languages
English (en)
Chinese (zh)
Inventor
乔迪·迈克尔·梅森
安德鲁·布雷南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bath
Original Assignee
University of Bath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bath filed Critical University of Bath
Publication of CN118984835A publication Critical patent/CN118984835A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380033105.4A 2022-03-11 2023-03-10 c-Jun拮抗剂肽 Pending CN118984835A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2203399.7 2022-03-11
GBGB2203399.7A GB202203399D0 (en) 2022-03-11 2022-03-11 c-jun antagonist peptides
PCT/EP2023/056243 WO2023170302A1 (en) 2022-03-11 2023-03-10 C-jun antagonist peptides

Publications (1)

Publication Number Publication Date
CN118984835A true CN118984835A (zh) 2024-11-19

Family

ID=81254979

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380033105.4A Pending CN118984835A (zh) 2022-03-11 2023-03-10 c-Jun拮抗剂肽

Country Status (7)

Country Link
US (1) US20250188151A1 (https=)
EP (1) EP4490176A1 (https=)
JP (1) JP2025510591A (https=)
CN (1) CN118984835A (https=)
CA (1) CA3245706A1 (https=)
GB (1) GB202203399D0 (https=)
WO (1) WO2023170302A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118252913B (zh) * 2024-02-07 2024-09-17 中国医学科学院阜外医院 多肽偶联物及其在射血分数保留的心衰中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
US20100029552A1 (en) * 2004-08-20 2010-02-04 Phylogica Limited Peptide inhibitors of c-jun dimerization and uses thereof
GB201820863D0 (en) 2018-12-20 2019-02-06 Univ Bath Screening assay
GB202009710D0 (en) 2020-06-25 2020-08-12 Univ Bath Cross-linking methods

Also Published As

Publication number Publication date
CA3245706A1 (en) 2023-09-14
US20250188151A1 (en) 2025-06-12
WO2023170302A1 (en) 2023-09-14
GB202203399D0 (en) 2022-04-27
JP2025510591A (ja) 2025-04-15
EP4490176A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US11912794B2 (en) Modulation of structured polypeptide specificity
JP6785932B2 (ja) 構築されたポリペプチド特異性のモジュレーション
US20230137773A1 (en) Ras inhibitory peptides and uses thereof
Ayers et al. Introduction of unnatural amino acids into proteins using expressed protein ligation
DK2320927T3 (en) Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
US20240294574A1 (en) Stabilized peptides for covalent binding to target protein
US12466853B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
KR20230022168A (ko) Psd-95의 사이클릭 펩타이드 억제제 및 이의 용도
Jiang et al. Macrocyclic peptides as regulators of protein-protein interactions
Monsarrat et al. Iterative structure-based optimization of short peptides targeting the bacterial sliding clamp
US20250188151A1 (en) C-jun antagonist peptides
EP2697249B1 (en) Compounds binding to the bacterial beta ring
JP2006503088A (ja) ターンライブラリーをファージ上にディスプレイするための構造化ペプチド骨格
Rathman Design and Synthesis of Biologically Relevant N-Aminated Macrocyclic Peptidomimetics
Horsfall et al. Designing fluorescent nuclear permeable Peptidomimetics to target proliferating cell nuclear antigen
Werner Structural and Functional Impacts of Chemical Modifications in Peptides and Small Proteins
Berg Structure Affinity Relationship Study of Macrocyclic Peptide Scaffold Binding to PSD-95
Christensen Designing and stabilising peptide-protein interactions
Yavorova Engineering constrained peptides to target nucleic acids: G-quadruplex recognition and imaging
Johnson et al. Exploratory synthesis of peptide–α‐thioester segments spanning the polypeptide sequence of the δ‐opioid receptor, a G protein‐coupled receptor
Liu Development of cyclic peptidyl ligands through a combinatorial library approach
HK1252864B (en) Modulation of structured polypeptide specificity
Zhang Discovery of anti-apoptotic macromolecular cancer therapeutics and development of a biocompatible nanoparticle system for targeted drug delivery
Hurd Development of stapled peptides targeting
Park Design of β-hairpins and β-sheets for molecular recognition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination